Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 4

Sponsor Class

OTHER 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4Other solid neoplasm 1Gastrointestinal 1

Conditions

Breast Neoplasms 3Breast Cancer Metastases 1

Interventions

Trastuzumab 732Paclitaxel 695Cyclophosphamide 647Docetaxel 560Capecitabine 486Letrozole 437Fulvestrant 400Carboplatin 398Doxorubicin 341Tamoxifen 308Anastrozole 279pembrolizumab 274exemestane 258Epirubicin 251pertuzumab 240Radiotherapy 239palbociclib 224Bevacizumab 222Gemcitabine 215Vinorelbine 197Lapatinib 181130-nm albumin-bound paclitaxel 172Magnetic Resonance Spectroscopy 164Albumin-Bound Paclitaxel 157eribulin 154Surveys and Questionnaires 152Exercise 151Drug Therapy 141Taxes 134Fluorouracil 133

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
zirconium-89-trastuzumab × Breast × Clear all
NCT01565200 2025-03-31

ZEPHIR

Jules Bordet Institute

Phase 2 Completed
90 enrolled
Breast

Breast Neoplasms

NCT02286843 2021-06-18

Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?

Memorial Sloan Kettering Cancer Center

Phase NA Completed
49 enrolled 8 charts
Breast

Breast Cancer Metastases

NCT01832051 2015-11-05

Clinical Value of 89Zr-trastuzumab PET

University Medical Center Groningen

Phase 2 Completed
20 enrolled
Breast

Breast Neoplasms

NCT01081600 2013-05-14

AUY922

University Medical Center Groningen

Completed
7 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡